By using the TIDE (tumor immune dysfunction and exclusion) program [56, 57], SERPINB8 predicts resistance to ICB in 14 of 25 cohorts at AUC values > 0.5, including NSCLC (AUC 0.68), melanoma (AUC 0.72), and gastric cancer (AUC 0.76). This evidence concerns the gene SERPINB8 and non-small cell lung carcinoma.